Scherer/Marquest
This article was originally published in The Gray Sheet
Executive Summary
Enter into a definitive agreement under which Scherer will provide up to $4.5 mil. in financing to Marquest and will guarantee up to an additional $3 mil. for working capital. Marquest will use the $4.5 mil. for capital additions, to pay off short-term credit and for operating expenses. The firms also will work to refinance Marquest's defaulted Swiss bonds, which amount to about $12.6 mil. The definitive deal's terms are different from those of a March 17 revised agreement in principle ("The Gray Sheet" March 22, p. 21). The March pact would have provided $4.5 mil. in financing, as well as $4.5 mil. through a guarantee of proposed mortgage debt. In conjunction with the agreement's transactions, Scherer may acquire up to about 65% of Marquest common stock and will be able to name the majority of Marquest's board members. Scherer also obtains rights to Marquest's ABG blood gas analysis product line, which it will license back to Marquest. Marquest will have a three-year right to repurchase the product line.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.